| Logo | Name | Σ | Employees |
|---|---|---|---|
 |  BioCryst Pharmaceuticals, Inc. We develop oral small-molecule and protein therapeutics to treat hereditary angioedema (HAE) and other rare diseases. BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. We are a commercial-stage biotech company with US headquarters in Durham, North Carolina. Our European headquarters is in Dublin, Ireland, and our Discovery Center of Excellence is rooted in Birmingham, Alabama, with many other regional offices … 151 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 611 |
 | CENTOGENE Empowering precision medicine through advanced diagnosis CENTOGENE is a leading company in the field of genetic diagnostics and precision medicine, dedicated to transforming clinical, genetic, and biochemical data into medical solutions for patients. Based in Rostock, Germany, the company operates globally. Founded in 2006 with the mission of revolutionizing the diagnosis of rare diseases, CENTOGENE has since scaled its capabilities to diagnose more than 2,500 rare diseases in over 100 countries, building one of the largest genetic databases in the world (1,000,000 individuals) while developing cutting-edge technology for the interpretation of genetic data. With over 350 scientific publications, CENTOGENE is … 155 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 25 | 404 |
 |  Generare Natural molecule discovery, industrialized Natural products have contributed more than 500 molecules to pharmaceuticals. However, conventional methods for discovering new natural products are increasingly ineffective. Generare has developed a revolutionary platform that identifies and expresses a wide range of naturally occurring secondary metabolites, selected by millions of years of bacterial evolution. This platform allows us to reintroduce these lead molecules into clinical pipelines, reopening a validated avenue for therapeutic innovation. genomics, synbio, and microbiology 100 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 8 | 21 |
 | Meddenovo Drug Design Meddenovo offers a unique blend of AI technologies and molecular modeling to design cyclic peptide therapeutics. Meddenovo is advancing AI-driven drug discovery with a specialized technology platform designed specifically for cyclic peptides. Our platform can design cyclic peptides from scratch, even without prior experimental data, and incorporates cutting-edge technology to capture their chameleon-like properties, including cell permeability. This unique capability enables us to address previously undruggable targets with precision. Cyclic peptides are a transformative class of compounds in pharmaceutical research, offering the advantages of both small molecules and large biologics, such as exceptional binding affinities, stability, and specificity. Technological advancements … 10 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Synthetic Biology | 4 | 8 |
 | Nimbus Therapeutics We develop breakthrough medicines for patients through precision small molecule design. Nimbus Therapeutics is a clinical-stage, structure-based drug discovery company developing novel small molecule medicines designed to act against well-validated but difficult-to-drug targets implicated in multiple human diseases. The company advances promising research based on a unique strategy that combines leading-edge computational technologies with a tailored array of machine learning-based predictive modeling approaches. Nimbus' pipeline includes a clinical-stage HPK1 inhibitor for the treatment of cancer (NCT05128487), as well as a diverse portfolio of preclinical programs focused on cancer, including a WRN program for MSI-H cancers, autoimmune conditions, and metabolic diseases. … 60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 10 | 108 |
 | Ksilink Patient-based drug discovery We design and apply unique patient-based cellular assays for large-scale phenotypic screening, leaning on the power of AI-driven image analysis. Integrated from bed to bench and back to bed, we aim to generate most efficient first-in-class therapeutic molecules for next generation medicine. AI image and data analysis, biology, high content screening, high throughput screening, deep learning, assay development, patient stratification, pyschiatric disorders, and cardiac muscle 235 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: A.I. Synthetic Biology | 4 | 20 |
 | Lexicon Pharmaceuticals, Inc. At Lexicon, We Pioneer Medicines that Transform Patients' Lives Corporate Overview Lexicon Pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. Our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. The Genome: Our Source of Discovery We have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. Our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. We have integrated a series of recombinant DNA and chemistry technologies … 64 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 321 |
 | DeepLife AI for digital twin of cells DeepLife is an early stage startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, backed by international investors, developing the first SaaS platform for Digital Twin of cells. While we are able to design and build incredibly complex mechanical engines, engineering biological systems, such as cells, remains a challenge. However, recent technological improvements, notably in biochemistry, recently enabled the construction of databases with millions of quantitative cell activity measures, covering multiple diseases. The DeepLife team develops a SaaS platform combining state-of-the-art deep learning algorithms on multi-omics sequencing data, public and private cell atlases, … 91 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Deep Learning SaaS | 27 | 30 |
 | Ranomics Ranomics offers innovative solutions for protein engineering, drug discovery, genomics research and synthetic biology Ranomics offers high throughput solutions for protein engineering, drug discovery, genomics research and synthetic biology. Using our VariantFind and VERG genomics platforms, Ranomics offers partners the a scalable solution to engineer and screen genetic variants in a wide range of model organisms. Our industry leading DNA Variant libraries and high-throughput cell assays help researchers to hit their research objectives faster and with better results than traditional methods. Over the years, we have worked with top biotech and pharma companies in the US and worldwide. Our partners … 186 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 7 |
 | Biosortia, Inc. Unlocking the Hidden Chemistry of Microbiomes for Next-Generation Therapeutics with ISMM • Expanding Customer Pipelines Biosortia Pharmaceuticals is pioneering a revolutionary approach in drug discovery through its Industrial Scale Microbiome Mining (ISMM) technology. By accessing the vast, untapped chemical diversity found within natural microbiomes, We unlock a hidden world of small molecules that play crucial roles in cellular signaling and disease processes. These small molecules, often referred to as the "drug-like dark matter" of cellular biology, have been largely inaccessible until now. Our technology allows for the large-scale harvesting and exploration of these compounds, providing an unprecedented opportunity to discover … 69 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Data Analytics Synthetic Biology Generative A.I. A.I. - Machine Learning | 1 | 10 |
 |  Calico Biosystems Predicting life-changing drugs for patients with cancer Calico Biosystems is on a mission to help pharma companies create effective, affordable drugs faster to counter cancer multi-omics assay, computational modeling, drug efficacy prediction, combination therapy, and Cell and virus-based therapeutics' efficacy 543 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 2 | 1 |
 | Serna Bio Mapping the druggable transcriptome An estimated 85% of the ~3 billion base pairs in the human genome is transcribed into RNA, but only ~1.5% of these code for proteins. While the chemical properties of protein binders are increasingly understood and interrogated, the field of RNA-targeted drugs is relatively new and the properties of small molecules that drive specific and selective targeting of RNA, and associated assays, are yet to be developed. At Serna Bio [previously Ladder Therapeutics] we are using an AI enabled, data-first approach to write the rules that define RNA-small molecule interactions. Our Discovery Platform powers our first-in-class … 15 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology | 0 | 15 |
 | Depixus Depixus SAS, based in Paris, is a life science technology company pioneering a groundbreaking technology based on magnetic force spectroscopy. This innovative technology provides real-time analysis of individual biomolecular interactions at scale, enabling researchers to decode disease mechanisms and unlock faster routes to more effective therapies. Single molecule analysis, RNA Drug Discovery, Protein-protein Interaction Analysis, Biophysics, Drug Discovery, Compound Screening, biomolecular interactions, and interactomics 159 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 2 | 57 |
 | AQEMIA Scale Drug Discovery with Quantum-inspired Physics and AI AQEMIA is a next-gen pharmatech company generating one of the world's fastest-growing drug discovery pipeline. Our mission is to design fast innovative drug candidates for dozens of critical diseases, such as immuno-oncology. Our unique approach leverages quantum-inspired physics algorithms to power generative AI in designing novel drug candidates—without relying on experimental data. We already delivered several drug discovery successes within our internal pipeline and through collaborations with pharmaceutical companies. Our most advanced programs are currently in vivo optimization. AQEMIA is based in Paris and London. We are growing and hiring! Check our … 32 similar entities Tags: FrenchTech120 FrenchTech2030 Type: Startup Activities: deeptech healthtech Technologies: A.I. Generative A.I. Synthetic Biology | 69 | 75 |
 | Qubit Pharmaceuticals Anything is Druggable - with Quantum Accuracy Qubit Pharmaceuticals brings unparalleled accuracy and precision to drug discovery and design, using quantum physics to develop life-changing treatments for major diseases. We leverage our technologies and expertise to advance 7 fully owned drug discovery programs focusing on cancer resistance and escapement, a growing concern in aging populations, and chronic inflammatory diseases. We also co-develop programs with academia and pharmaceutical partners. Our proprietary ATLAS drug discovery platform unites our technologies based on 30 years of research from renowned scientists and founders, Louis Lagardère (Sorbonne University and CNRS), Matthieu Montes (CNAM), Jean-Philip Piquemal (Sorbonne … 70 similar entities Tags: FrenchTech2030 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 68 | 72 |
 | Absci Unlocking differentiated biology with generative AI Absci is a data-first AI drug creation company designing differentiated therapeutics using generative AI. Our Integrated Drug Creation platform powers cutting-edge de novo AI models and AI lead optimization models aimed at designing better biologics against difficult-to-drug targets. generative AI, synthetic biology, biologics, drug discovery, antibody development, artificial intelligence, pharmaceuticals, and biotechnology 80 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Deep Learning Generative A.I. Synthetic Biology | 11 | 190 |
 | Oxford Drug Design A drug-discovery company focused on oncology. Follow us on Twitter @OxDrugDes Oxford Drug Design, an advanced spinout from Oxford University, is an innovative biotechnology company discovering and developing novel therapeutics supported by pioneering computational methods. We design innovative drugs with differentiated modes of action against cancer and other challenging diseases with high unmet medical need seeking superior patient outcomes. Based on the unique integration of our dual core competences in aminoacyl-tRNA synthetase enzymes and distinctive AI/ML methods, our pipeline expansion is focused on oncology. This distinctive drug discovery platform has been validated by the rapid discovery of novel therapeutic candidates … 101 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology A.I. - Machine Learning A.I. | 5 | 10 |
 | Anuva Creating the world’s most diverse Genomic Bio/Data Bank to help uncover novel biological pathways for drug discovery Anuva is creating the world’s most diverse Genomic Bio/Data Bank to help uncover novel biological pathways for drug discovery. Anuva is a translational research company that is creating the most diverse Genomic Bio/Data Bank of Asian Populations, which is being utilized for research & development within the pharma industry. Our cohorts and biorepository allow for follow-on clinical and translational studies, which greatly empower drug development opportunities. IndiaCHIP, Genomics, Genomics - Emerging markets, Genomics - R&D, Genomics Data Platform, Genomics - India, bioinformatics, and … 65 similar entities Type: Startup Activities: biotech deeptech Technologies: Data Analytics Synthetic Biology | 8 | 60 |
 | 1910 Genetics Advancing small and large molecule drug discovery with a multimodal AI platform powered by laboratory automation. 1910 Genetics is the only biotechnology company advancing small and large molecule drug discovery with a multimodal AI platform powered by laboratory automation. We integrate AI with three proprietary data streams – computational data, wet lab proxy biological data, and wet lab ground truth biological data – to deliver novel drug candidates and software solutions to leading pharma and tech partners, and advance our internal pipeline for neurological, autoimmune diseases, and cancer. We are backed by leading investors including M12 - Microsoft's Venture Fund, … 89 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Data Analytics Synthetic Biology | 2 | 33 |
 | Integrated Biosciences, Inc. Unravelling complex biology with optogenetics, chemistry and computation for small molecule discovery. Our platform is built around a proprietary synthetic biology toolkit, featuring advanced optogenetic tools that enable precise temporal and spatial control of complex pathways and difficult-to-drug targets. Powered by vast proprietary datasets and cutting-edge AI models, our platform accelerates drug discovery and facilitates the generation of novel chemical matter, unlocking solutions for even the most challenging biological systems. biotechnology, aging, drug discovery, machine learning, synthetic biology, optogenetics, artificial intelligence, small molecule, rejuvenation, molecular biology, and novel therapeutics 203 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Synthetic Biology A.I. - Machine Learning | 1 | 10 |
 | Talus Bio Gene regulator profiling in live cells for drug development Talus Bioscience is a venture-backed early-stage biotechnology startup company working on drug development for gene regulators. Talus Bio spun out of two leading institutions in September 2020 (University of Washington and Altius Institute for Biomedical Sciences) and is located in Seattle, WA. We are building a data-enabled drug development platform that will focus primarily on small-molecule drug development in oncology. Talus Bio's platform measures a drug’s ability to disrupt a gene regulator within its natural, non-engineered cellular environment. Furthermore, a single experiment using the platform measures activity for about 1,000 gene … 60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 24 |
 | PhoreMost Ltd Drugging the Undruggable® PhoreMost is a new-model drug discovery company based in Cambridge, UK. We are dedicated to ‘Drugging the Undruggable®’ disease targets using our next-generation technology, SITESEEKER®. Using PROTEINi® libraries, this unique drug target identification platform can discern the best new targets for future therapy and crucially, how to drug them, which has the potential to significantly increase the diversity and affordability of novel therapeutics for cancer and other unmet diseases. PhoreMost is building a pipeline of novel drug discovery programmes aimed at addressing a range of diseases, with a mission to accelerate, diversify and rationalise drug discovery. Using … 63 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 6 | 48 |
 | Delta4ai Delta4 is a Vienna-based biotech startup driving the forefront of digital drug discovery and development. Delta4 is driving the forefront of digital drug discovery and development. We leverage a proprietary computational analytics platform "Hyper-C", combining straightforward biomedical testing and clinical validation of candidate drugs. Our unique approach integrates iterative big data/in silico and experimental screens, offering the most efficient matching of clinical indications and compound/drug effects. drug repositioning, drug discovery, compounds, orphan diseases, indication expansion, AI, and omics 67 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology | 4 | 14 |
 | InterAx Biotech Advanced integration of biological systems, math models and artificial intelligence The company, a spin-out of ETH Zurich and the Paul Scherrer Institute, Switzerland, uses high throughput biochemical screening of compounds integrated into an artificial intelligence and cell pathways mathematical modeling process. This platform unlocks previously intractable targets, shortens timelines for drug discovery from years to months and reduces risks. The company focuses on the generation and optimization of drugs which trigger a specific and well characterized effect on signaling pathways, thus leading to higher therapeutic efficacy and reduced risk of toxicity. The company is specialized in GPCR drug discovery and … 113 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology | 4 | 15 |
 | Insilico Medicine #insilicomeds, #drugdiscovery, #ai, #GANs, #GANs-RL, #DL #aging, #longevity Insilico Medicine, a clinical stage biotech company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. artificial intelligence, deep learning, reinforcement learning, drug discovery, … 57 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Deep Learning Generative A.I. Synthetic Biology | 21 | 279 |
 | Abtech Therapeutics Expertise in protein engineering | in silico & in vitro antibody discovery platform We work in partnership with technology platforms, pharmaceutical companies, and academic research groups to create next generation cell and molecular therapies. We integrate novel technologies into a synthetic antibody platform to provide the most advanced discovery engine possible. 259 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 2 |
 | miRecule, Inc. RNA Therapeutics We develop first-in-class RNA-based therapies, with lead programs in Head & Neck Squamous Cell Carcinoma (HNSCC) and Facioscalpulohumeral Muscular Dystrophy (FSHD). Our approach to drug design revolves around using genomic patient data to create highly tailored therapeutics – the right drug for the right patient. Our proprietary DREAmiRTM platform utilizes genomic and outcome data from thousands of patients to identify underlying genetic changes that cause their disease, and then creates a novel RNA therapeutic that can directly target and fix that genetic abnormality. 113 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology Data Analytics | 2 | 15 |
 | Anima Biotech We believe the only way to discover better, life-changing drugs is by seeing diseases in action, not guessing them. That’s why at Anima Biotech, we’ve built the AI platform that thinks, sees, and learns biology at the core of disease mechanisms, inside real patient-derived cells. Anima Biotech is a TechBio pioneer, transforming target and drug discovery with Lightning.AI - the first Visual Biology loop where Computational and Experimental AI agents iteratively think, see, and learn disease pathways, turning the undruggable into tomorrow’s therapies. Lightning.AI runs two AIs in one discovery loop - Computational AI that thinks of thousands of hypotheses … 48 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology A.I. | 5 | 67 |
 | Vitroprobe Analytics Vitroprobe Analytics performs biomolecular analysis at the atomic scale to help design the pharmaceuticals of tomorrow. Vitroprobe Analytics performs biomolecular analysis at the atomic scale to help design the pharmaceutical drugs of tomorrow. The development of new effective pharmaceutical drugs to fight disease is a slow and expensive process. Successful drug design relies on a profound understanding of the interactions between drug candidates and their target molecules in the body. The company has developed a unique platform to analyze target molecular structure in3D with simultaneous identification of individual constituent atoms. With the novel patented technique drug targets can be examined … 21 similar entities Type: Startup Activities: biotech deeptech Technologies: Data Analytics | 0 | 5 |
 | Zymvol Biomodeling Accelerating enzyme discovery and design through computer simulations We are a biotech company that delivers tailor-made enzymes designed to outperform client's needs. At Zymvol we combine cutting edge technology with top scientific expertise to make biocatalysis available to everyone. We are a trusted partner that supports our customers in every stage of their bio-journey: from project definition and prioritization to the development and delivery of tailored enzymes. Our unique approach enables unparalleled accuracy and predictability, along with unprecedented speed. We are the perfect partner for companies aiming to maximize their return on investment and meet their timelines in biocatalysis development. … 65 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 9 | 32 |
 | Enzymlogic Enzymlogic is a world leader in the kinetic profiling of compounds to facilitate drug discovery. Enzymlogic is a world leader in the kinetic profiling of compounds to facilitate drug discovery. As experts in the generation and interpretation of kinetic data, we pride ourselves on a proven track record of successful partnerships with worldwide organizations of all sizes, supporting them on a routine basis during the early phases of drug discovery. We use exquisitely tuned assays to deliver accurate, robust and reproducible kinetic data of the highest quality that enhances the identification of compounds with the greatest therapeutic potential. The insight … 25 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 10 |
 | Platinum Discovery Multiomics research for precision medicines Platinum Discovery offers a cutting-edge Tumour-to-Target Platform, specialising in cancer vaccine development through the identification of tumour-specific neoantigens. We provide a comprehensive, end-to-end drug discovery pipeline, supporting clinical trial research and translational science for patient samples. Our multidisciplinary team brings together expertise in biology, clinical sciences, multi-omics technologies, bioinformatics, and computational sciences, enabling a deep understanding of the biological processes critical to drug development. We excel at integrating diverse scientific domains to deliver holistic, innovative solutions. With extensive experience in designing and managing complex research programmes, we assemble tailored teams of experts, drawing on our … 112 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 4 |
 | OPPILOTECH LTD Navigating Biology, Discovering Drugs Oppilotech have developed a high-resolution platform based on systems biology and machine learning to model biological processes in cells. We use the models to simulate biological processes in order to identify viable drug targets and discover new biology. The company is building a pipeline of first-in-class drug discovery programmes based on the identified targets. 86 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology A.I. A.I. - Machine Learning | 1 | 11 |
 | MolDrug Chemoinformatics and modeling solutions to optimize your drug candidates. MolDrug (a ProtoQSAR company) is a group specializing in the design and optimization of molecules through Machine Learning-powered chemoinformatics and structural bioinformatics. Our models allow for the prediction of molecular properties (QSAR) and detailed interaction analyses (molecular modelling). We work with all types of compounds, including small molecules, peptides, nanomaterials, mixtures... Our tools allow for the prediction and assessment of physicochemical, biological, pharmacological, and/or (eco)toxicological properties of substances with an array of advantages: - faster results - saving money and resources - reduce animal testing (3 Rs) - regulatory validity (REACH, … 61 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 4 |
 | Relation Discovering the relationships at the heart of biology to cure disease. We are an end-to-end biotech developing transformational medicines, with technology at our core. Our ambition is to understand human biology in an unprecedented way; discovering therapies that will treat some of life's most devastating diseases. We leverage single-cell and multi-omics measurements directly from patient tissue, functional assays and machine learning to drive disease understanding — from cause to cure. Medicines born from high-resolution biology, machine learning and clinical insights. Our Lab-in-the-Loop seamlessly integrates single-cell analysis, genomics and machine learning. We have developed powerful technologies which we apply to select … 81 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 14 | 86 |
 | Aureus Pharma Aureus Sciences focuses on providing solutions to the needs of pharmaceutical and biotech companies to leverage information and knowledge as a decision making tool and to increase the speed and efficiency of their drug discovery and development process. Over the course of 10 years and with a significant investment, the Company has developed a unique Knowledge Production Platform which analyzes, indexes and organizes critical chemical and bioactivity information into databases. Using this platform the Company provides best-in-class, scientific databases and associated software applications for use by researcher involved in the drug discovery and development process.The company's range of products includes … 106 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 2 |
 | DISCO Pharmaceuticals GmbH The surfaceome company. DISCO’s pioneering surfaceome mapping platform transforms the current approach of target discovery for large molecule R&D. The technology identifies proteins and protein communities across the entire cancer cell surface in a scalable manner, thus addressing the need for target candidates for both mono- and bi-specific antibodies. These insights enable the development of a multitude of cancer-selective therapies, with the potential to boost efficacy and reducing side effects for patients. 32 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 26 |
 | Treventis Corporation TREVENTISTM Corporation is dedicated to treating and preventing protein misfolding diseases. We utilize a proprietary, patent-pending discovery engine – Common Conformational Morphology (CCM) – to identify druggable active sites in misfolded protein targets. CCM combines unique in silico models with deep expertise in model development (in vitro, ex vivo, in vivo) to enable rational drug design against misfolded protein targets. Our lead program focuses on anti-misfolding small molecules in tauopathy (3R, 4R, familial mutations and mixed) with relevance to Alzheimer’s disease. We have further CCM-driven efforts in oncology and other neurodegenerative diseases that show the wide utility of our technology … Type: Startup Activities: healthtech deeptech biotech Technologies: Synthetic Biology | 1 | 18 |
 | InFocus Therapeutics Innovating a New Class of Medicines to Drug the Undruggable InFocus is a discovery-stage biotechnology company dedicated to true innovation for novel therapeutic modalities. We are integrating unique experimental technologies with a state-of-the-art algorithm-driven drug discovery platform, to develop next-generation small molecule drugs against undruggable targets at unprecedented scale. 119 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 3 | 11 |
 | Cellarity Rewriting the rules of drug creation Cellarity is fundamentally redesigning the way drugs are created. By shifting the focus from a single target to the underlying cellular dysfunction, the company unravels the complexity of disease biology to create medicines that are out of reach with the target-based drug discovery approach. Founded by Flagship Pioneering in 2017, Cellarity has developed a platform that utilizes proprietary AI models trained on over 30 million single cell transcriptomes to uncover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs ongoing in several disease areas … 281 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology | 4 | 104 |
 | Kuano Providing innovative quantum and AI solutions for drug discovery and design. Our discovery platform uniquely combines target quantum mapping and AI led chemistry to enable faster development of better drug candidates. Our unique approach tackles common challenges in both AI driven drug design and target driven drug discovery. Quantum Mapping of targets introduces selectivity from the start, producing superior candidates in fewer design rounds. Identifying better starting points for AI-led chemistry eliminates bottlenecks in the hit to candidate optimization phase. Generating better Enzyme Inhibitors by targeting Quantum Transition States. We work with enzyme inhibitors in a unique way, continually developing … 14 similar entities Type: SMB Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology | 2 | 17 |
 | MedFacts Drug discovery with cutting-edge AI technology We’re pioneering the use of AI and shaping the future in drug discovery, significantly cutting costs and development times. Our unique AI algorithms have generated novel drug candidates and identified enhancements for existing therapies more efficiently than traditional methods, setting us apart in the competitive landscape. Artificial Intelligence, Data Science, Health, Medicines, and Drug development 146 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 1 |
 | InVirtuoLabs Unlocking a bold new world of transformative drug discovery InVirtuoLabs is a new-generation laboratory for drug discovery. We design novel drugs by combining advanced machine learning techniques with physics-based simulations to rapidly identify and optimize promising drug candidates. 87 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. A.I. - Machine Learning Synthetic Biology | 1 | 11 |
 | PharmEnable Therapeutics Harnessing the power of chemical novelty, diversity and 3-dimensionality to develop innovative small molecule drugs PharmEnable is a biopharmaceutical company utilizing AI to discover effective small-molecule medicines for disease targets that are inaccessible to antibodies. With our proprietary AI-enabled drug discovery platform, chemSEEK, we explore new chemical spaces and discover novel small molecules with antibody-like specificity and selectivity. We are developing a pipeline of wholly owned therapeutics with initial focus on oncology and neurology. We also engage in drug discovery partnerships across a range of disease areas where accessing the target poses a significant challenge. PharmEnable is based in Cambridge, … 111 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 6 | 20 |
 | Mosaic TX Resolving cancer's complexity through the power of targeted drug combinations ABOUT US Mosaic Therapeutics is an oncology therapeutics company delivering precision medicines for patient groups with few targeted treatment options today. The company’s main mission is to tackle cancers with substantial unmet need by reinventing the traditional approach to target and drug discovery - leveraging our differentiated dual technology platform to advance novel combination therapies. Born out of pioneering research at the Wellcome Sanger Institute in collaboration with the Netherlands Cancer Institute, and anchored around a proprietary platform that has seen 20 years of fine-tuning and development, Mosaic has active … 160 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 25 |
 | Galactica Biotech Galactica Biotech provides a drug repurposing method to identify novel applications for molecules in the market and in development for major and orphan diseases, reducing risk for patients and time and cost for companies. Our Mission With our specialized knowledge we are targeting to set new standards in the pharmaceutical industry adding value to old drugs and contributing to the health of people. Drug Discovery, Molecule characterization, Drug repurposing, and Novel compound applications 290 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology | 0 | 1 |
 | Curve Therapeutics Revolutionary intracellular screening platform enables a new generation of first-in-class drugs. Our mission is to transform the discovery of first-in-class small molecule therapeutics by broadening the landscape of disease targets that can be drugged. Our Microcycle® platform enables direct screening for biologically active hits inside mammalian cells and creates a toolkit for hit-to-lead programmes. We are deploying our innovative platform to build a pipeline of first-in-class small molecules to address high priority, therapeutically relevant cancer targets. 63 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 35 |
 | Sequence Bio Discovering the true signals of disease to power life-changing medicines. 90% of drug candidates fail, delaying help for those in need. We’re on a mission to change that with better, faster drug target discovery powered by the Newfoundland founder effect. Biotechnology and Drug Discovery 90 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 19 |
 | MEDIBIOFARMA SL To make disease-modifying treatments available to patients with serious or life-threatening conditions Medibiofarma S.L is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. We aim to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, IP generation, IBD (Colitis, Crohn), Oncology, CNS, and Synaptopathies 540 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 9 |
 | Invitris A startup using Synthetic Biology to innovate the way we develop entirely novel classes of protein-based drugs. Our patent-pending biotech platform, Phactory, makes designing synthetic proteins 10,000x more effiicent and reduces the material costs by 100x. We are leveraging Phactory to develop the newest classes of protein-based drugs, such as the next generation of antibiotics. 126 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 18 |
 | CardiaTec Bio Decoding cardiovascular disease biology for novel therapeutic discovery CardiaTec is a TechBio company employing computational methods to decode the biology behind cardiovascular disease. We leverage large and high-dimensional human omics data to better navigate complex disease biology to discover novel and differentiated therapeutics. 88 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 6 | 13 |
 | BenevolentAI Accelerate scientific breakthroughs with AI BenevolentAI is a pioneer and leader in applying advanced AI to drug discovery and development. In a world where drug development failure rate exceeds 90% and thousands of complex diseases lack treatment, our technology can increase the probability of success and reduce timelines. Our proprietary Benevolent PlatformTM is one of the industry's most established and validated AI drug discovery technologies. Expertise across Target Identification, Chemistry and Drug Repurposing enables us to deliver across the entire R&D lifecycle. We unite science and technology to serve patients with complex diseases – because it matters. BenevolentAI is headquartered … 75 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. A.I. - Machine Learning Data Analytics A.I. - Deep Learning | 33 | 131 |
 | AUM Biosciences Advancing precision oncology therapeutics designed to deploy multi-faceted inhibition to reverse cancer resistance AUM Biosciences is focused on advancing a clinical pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance biotech, oncology, drug development, Asian-biotech, Precision medicine, Digitalhealth, cancer, and small molecules 550 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 17 |
 | Selvita Integrated Drug Discovery | Drug Development | Contract Research Selvita is one of the largest preclinical contract research organizations in Europe, driven by a clear mission: to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development. biotechnology, pharmaceuticals, drug discovery, preclinical research, bioanalytical development services, bioinformatics, systems biology, proteins, genomics, proteomics, autoimmune disorders, regulatory studies, medicinal chemistry, agrochemical, industrial chemistry, and assay development&screening 504 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 771 |
 | Sygnature Discovery Sygnature Discovery is a world-leading integrated drug discovery contract research organization based in the UK and Canada with headquarters in Nottingham (UK). Additional sites are located in Alderley Park, Macclesfield, and Glasgow (UK), as well as Montreal and Quebec City (Canada). Its team of over 1,000 employees, which includes 900 scientists, partners with global biotech, pharma and NFP organizations. Since 2011, Sygnature Discovery has delivered 50 novel pre-clinical and 30 clinical compounds, with its scientists named on over 170 patents. Therapeutic areas of expertise include oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases, and more. Founded in … 79 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 15 | 664 |
 | Antiverse Designing functional antibodies for the most challenging targets. Antiverse is a Welsh techbio company specialising in antibody design for challenging drug targets, such as GPCRs and ion channels. We exist to create new enabling technologies that bring new therapies to patients to change lives. Headquartered in Cardiff, UK and with offices in Boston, MA, we combine state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. Machine Learning, Antibodies, and Drug discovery 104 similar entities Type: SMB Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Generative A.I. Synthetic Biology | 7 | 23 |
 | Reaction Biology Contract research organization with commitment to quality data and quality support. Let's Discover Together. Reaction Biology provides scientists worldwide with a trusted research partner supporting all phases of preclinical drug discovery from target validation through hit identification, hit to lead and lead optimization. Our portfolio covers most of your needs in drug discovery – over 2,000 biochemical targets, hundreds of cell-based assays, an extensive array of in vivo oncology models, along with custom assay development and protein production. Our team of Ph.D. scientists will provide you with collaborative support, quality data, and excellent communication, for a superior research result. Our … 30 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 135 |